Swedish bioprinting company CELLINK has partnered with organ and tissue engineering company Prellis Biologics, Inc. Establish a partnership with the goal of commercializing high-resolution holographic bioprinting technology for microscale printing. By combining their intellectual property and their respective expertise, these companies will launch what they call "the first system capable of microstructure ultra-high resolution bioprinting" for the production of vascular networks.
Holographic bioprinting technology will leverage and complement CELLINK's existing extrusion-based bioprinting technology and Prellis Biologic's proprietary multiphoton laser-based bioprinting platform.
Said Melanie Matheu, CEO of Prellis Biologics. "Not only will our team lead the development of discovery and treatment using realistic 3D structures, but global scientists. Putting this technology into the hands of dedicated researchers is bringing scientific advances to the clinic and providing solutions for the real population. The fastest way to plan. "
As part of the collaboration, CELLINK will be responsible for the design of bioprinting systems, including user interface development and sales of printers, inks and consumables to end users in the pharmaceutical industry and academia.
Holograph-X Bioprinter
The first product offered through the partnership will be CELLINK Holograph-X Bioprinter-powered by Prellis Biologics. It is understood that this advanced bioprinting system will cost about 1.2 million US dollars, becoming the first platform for vascularized tissue structure before bioprinting, and supports tissue growth 10 times larger than traditional spherical cultures.
The high-end system is compatible with any CAD file, enabling researchers to set their own organ and tissue culture goals. Bioprinters can also be used in the laboratory to make capillary-containing organ structures and tissues for transplantation, therapeutic screening, and complex 3D culture development.
CELLINK and Prellis emphasize that the forthcoming bioprinting technology can achieve a resolution that "matches the microvascular structure of human tissue and extracellular matrix." The development of the Hotograph-X Bioprinter is already underway, as the first commercial machine is expected to Launched in early 2019.
CELLINK CEO Erik Gatenholm said, "We are pleased to announce this partnership, where we combine the key strengths of both companies to provide our partners and customers with cutting-edge technology that enables them to advance their 3D in humans Research in the field of bioprinting ".
MedImmune cooperation
In other recent news from CELLINK, the bioprinting company has established a year-long partnership with MedImmune, AstraZeneca's global biologics research and development unit. Through this partnership, MedImmune will use CELLINK's bioinks to print tissues to explore new approaches to disease treatment. Bioprinted tissue will be used in a range of disease areas, including oncology, respiratory disease, cardiovascular disease, kidney disease and metabolic disease.
"This collaboration will further open up CELLINK's drug development unit and lay the foundation for future drug development processes," Gatenholm said. "MedImmune is a leader in biologics research and development and uses cutting-edge technology to drive the development of potential new therapies. Working with MedImmune is an honor and a great opportunity."
Last week, CELLINK also announced the acquisition of German biodistribution technology company Dispendix GmbH for € 5 million.